LY-2157299: all 22 studies that test it
Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.
- Umbrella Biomarker-Guided Therapy in NPCNot yet recruitingNCT04605562Phase 2
- Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or OvaryCompletedNCT03206177Phase 1Results posted
- A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular CarcinomaCompletedNCT02423343Phase 1/2Results posted
- A Study of LY2157299 in Participants With Advanced Hepatocellular CarcinomaCompletedNCT02178358Phase 2Results posted
- A Study of Galunisertib in Participants With Myelodysplastic SyndromesCompletedNCT02008318Phase 2/3Results posted
- A Study in Recurrent Glioblastoma (GB)CompletedNCT01582269Phase 2Results posted
- A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic CancerCompletedNCT01373164Phase 1/2Results posted
- Galunisertib Combined With Capecitabine in Advanced CRC With PMActive, not recruitingNCT05700656Phase 1/2
- Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal CancerWithdrawnNCT03470350Phase 1/2
- Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)CompletedNCT02906397Phase 1
- Study of Galunisertib in Healthy ParticipantsCompletedNCT02752919Phase 1
- A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic CancerCompletedNCT02734160Phase 1
- ExIST Study of LY2157299 (Galunisertib) in Rectal CancerActive, not recruitingNCT02688712Phase 2
- Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast CancerCompletedNCT02672475Phase 1
- Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT02452008Phase 2
- A Study of Galunisertib on the Immune System in Participants With CancerCompletedNCT02304419Phase 1
- A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)CompletedNCT02240433Phase 1
- A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the BodyCompletedNCT02154646Phase 1
- A Study of LY2157299 in Healthy ParticipantsCompletedNCT01965808Phase 1
- A Study of LY2157299 Monohydrate in Healthy VolunteersCompletedNCT01746004Phase 1
- Study of LY2157299 in Japanese Participants With CancerCompletedNCT01722825Phase 1
- A Study Combining LY2157299 With Temozolomide-based Radiochemotherapy in Patients With Newly Diagnosed Malignant GliomaCompletedNCT01220271Phase 1/2